LY4268989

DRUG4 trials

Sponsors

Eli Lilly and Company

Conditions

HealthyUlcerative ColitisUlcerative Colitis (UC)Ulcerative Colitis, Active ModerateUlcerative Colitis, Active Severe

Phase 1

A Study of LY4268989 (MORF-057) in Healthy Participants

CompletedNCT06964776

Eli Lilly and CompanyHealthy

Start: 2025-05-01End: 2026-02-17Updated: 2026-03-27

A Study of LY4268989 (MORF 057) in Healthy Participants

RecruitingNCT07707375

Eli Lilly and CompanyHealthy

Start: 2026-07-20End: 2026-10-01Target: 50Updated: 2026-08-20

Phase 2

LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:

RecruitingNCT07186101

Eli Lilly and CompanyUlcerative Colitis

Start: 2025-11-10End: 2029-03-01Target: 252Updated: 2026-09-08

LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis

RecruitingNCT07415044

Eli Lilly and CompanyUlcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe, Ulcerative Colitis (UC)

Start: 2026-03-26End: 2031-07-01Target: 1431Updated: 2026-09-08